AMD therapies in Phase II

Article

What therapies have made it to Phase II clinical trials?

                                   

 

ATG3 (CoMentis, formerly Athenagen): Nicotinic acetylcholine antagonist

ATG3 is a proprietary topical ophthalmic formulation of mecemylamine, an antagonist of the nicotinic acetylocholine receptor pathway that mediates angiogenesis, under investigation for the treatment of wet AMD.

CoMentis has initiated a Phase II study that will enrol 330 subjects to be randomized into one of three treatment groups: two different doses of ATG3 administered by eye drop twice daily, or placebo. All subjects will be monitored over a 48-week period to assess the drug' safety, tolerability and efficacy.

TG100801 (TargeGen): Anti-VEGF

TG100801 is administered non-invasively as an eye drop and is designed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, edema and angiogenesis.

TargeGen recently initiated a multicentre Phase II clinical trial of TG100801 in patients with AMD.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.